Trademarkia Logo

Canada

C$
PALISADE BIO
CANCELLED

Last Applicant/ Owned by

LEADING BIOSCIENCES

5800 Armada Drive,Suite 210Carlsbad CA 92008

US

Serial Number

2092843 filed on 29th Jan 2021

Registration Number

TMA1170243 registered on 8th Mar 2023

Registration expiry Date

29th Jan 2031

Correspondent Address

MARKS & CLERK

33 Yonge Street, Suite 300Toronto

ONTARIO

CA

M5E1G4

PALISADE BIO

Trademark usage description

pharmaceutical formulations and preparations namely oral and topical formulation to treat acute and chronic health conditions related to gastrointesti Read More

Classification Information


Class [005]
Pharmaceutical formulations and preparations namely oral and topical formulation to treat acute and chronic health conditions related to gastrointestinal, inflammatory, metabolic diseases in the nature of post-surgical ileus, adhesions, and injuries in the gastrointestinal tract, obesity, and cardiovascular disease, endocrine disease in the nature of diabetes, immunological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, oncological, hepatological, respiratory, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses, dermatological treatment of dermatitis, skin pigmentation diseases and psoriasis, and viral respiratory diseases and disorders; pharmaceutical compositions in liquid form, namely, liquid compositions containing protease inhibitors, to treat health conditions, diseases, and disorders related to the gastrointestinal tract, gastrointestinal permeability, the gastrointestinal epithelial barrier, gastrointestinal inflammation, the gastrointestinal immune system, the microbiome, and the gut-brain axis; pharmaceutical formulations and preparations to treat or prevent surgical complications and postsurgical complications; pharmaceutical formulations and preparations to treat or prevent shock, namely, acute shock, cardiogenic shock, septic shock, hemorrhagic shock, and shock associated with hypoperfusion; pharmaceutical formulations and preparations to treat or prevent gastrointestinal tract injuries, ileus, and adhesions; pharmaceutical formulations and preparations to treat or prevent multiorgan failure; pharmaceutical formulations and preparations to treat or prevent health conditions, diseases, and disorders related to intestinal permeability, the microbiome, and the gut-brain axis.


Classification kind code

11

Mark Details


Serial Number

2092843

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 48
on 16th Nov 2022
Agent Changed
Submitted for opposition 22
on 12th Jul 2022
Search Recorded
Submitted for opposition 20
on 12th Jul 2022
Examiner's First Report
Submitted for opposition 223
on 12th Jul 2022
Total Provisional Refusal
Submitted for opposition 256
on 18th Jan 2022
Notification of Possible Opposition Sent
Submitted for opposition 257
on 18th Mar 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 17th Mar 2021
Formalized
Submitted for opposition 1
on 17th Mar 2021
Created
Submitted for opposition 228
on 29th Jan 2021
International Registration
Submitted for opposition 30
on 29th Jan 2021
Filed